Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08RMH
|
||||
| Former ID |
DIB013841
|
||||
| Drug Name |
APC-2059
|
||||
| Synonyms |
BAY-44-3965
|
||||
| Indication | Inflammatory bowel disease [ICD9: 555, 556; ICD10:K50, K51] | Discontinued in Phase 2 | [1] | ||
| Company |
Celera South San Francisco
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
[C@@H]12[C@H](OC[C@H]2OC(=O)N2CCN(C(=O)NCc3ccc(NC(=N)N)<br />cc3)CC2)[C@H](OC(=O)N2CCN(C(=O)NCc3ccc(NC(=N)N)cc3)CC2)<br />CO1
|
||||
| Target and Pathway | |||||
| Target(s) | Tryptase | Target Info | Inhibitor | [2] | |
| Reactome | Activation of Matrix Metalloproteinases | ||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010270) | ||||
| REF 2 | Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther. 2002 Mar;16(3):407-13. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.